Enfusion (ENFN) Stock Forecast & Price Target

$9.38
+0.15 (+1.63%)
(As of 12:37 PM ET)

Enfusion Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Reduce
Based on 6 Analyst Ratings

Analysts' Consensus Price Target

$9.33
-0.50% Downside
High Forecast$11.00
Average Forecast$9.33
Low Forecast$8.00
TypeCurrent Forecast
4/24/23 to 4/23/24
1 Month Ago
3/25/23 to 3/24/24
3 Months Ago
1/24/23 to 1/24/24
1 Year Ago
4/24/22 to 4/24/23
Consensus Rating
Reduce
Reduce
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
Sell
3 Sell rating(s)
3 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$9.33$9.33$10.40$11.42
Predicted Upside-0.50% Downside4.48% Upside12.70% Upside3.10% Upside
Get Enfusion Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ENFN and its competitors with MarketBeat's FREE daily newsletter.

ENFN Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ENFN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Enfusion Stock vs. The Competition

TypeEnfusionComputer and Technology CompaniesS&P 500
Consensus Rating Score
1.67
2.59
2.49
Consensus RatingReduceModerate BuyHold
Predicted Upside1.12% Upside112.48% Upside11.05% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/13/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetUnderperform ➝ Underperform$8.00 ➝ $9.00-1.85%
2/28/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Sell$9.00 ➝ $8.00-14.26%
1/30/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underweight$11.00 ➝ $9.00+5.88%
12/20/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$9.00 ➝ $10.00+0.40%
11/7/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$9.00+8.56%
8/9/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$12.00 ➝ $11.00+31.74%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 12:55 PM ET.

ENFN Price Target - Frequently Asked Questions

What is Enfusion's consensus rating and price target?

According to the issued ratings of 6 analysts in the last year, the consensus rating for Enfusion stock is Reduce based on the current 3 sell ratings, 2 hold ratings and 1 buy rating for ENFN. The average twelve-month price prediction for Enfusion is $9.33 with a high price target of $11.00 and a low price target of $8.00. Learn more on ENFN's analyst rating history.

Do Wall Street analysts like Enfusion more than its competitors?

Analysts like Enfusion less than other Computer and Technology companies. The consensus rating for Enfusion is Reduce while the average consensus rating for computer and technology companies is Moderate Buy. Learn more on how ENFN compares to other companies.

Is Enfusion being downgraded by Wall Street analysts?

Over the previous 90 days, Enfusion's stock had 2 downgrades by analysts.

Does Enfusion's stock price have much upside?

According to analysts, Enfusion's stock has a predicted upside of 4.48% based on their 12-month stock forecasts.

What analysts cover Enfusion?

Enfusion has been rated by Bank of America, JPMorgan Chase & Co., and The Goldman Sachs Group in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:ENFN) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners